These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 4016278)
21. In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant. Sablayrolles M; Wajcman H; Castaigne JP; Labie D Haematologia (Budap); 1984; 17(2):199-207. PubMed ID: 6534828 [TBL] [Abstract][Full Text] [Related]
22. Antisickling effect of tellurite: a potent membrane-acting agent in vitro. Asakura T; Shibutani Y; Reilly MP; DeMeio RH Blood; 1984 Jul; 64(1):305-7. PubMed ID: 6733280 [TBL] [Abstract][Full Text] [Related]
23. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309 [TBL] [Abstract][Full Text] [Related]
24. An in vitro method for screening compounds for the effect on the rate of sickling of erythrocytes. Mackenzie RD; Gleason EM; Schatzman GL; Cawein MJ J Int Med Res; 1976; 4(6):375-81. PubMed ID: 1027632 [TBL] [Abstract][Full Text] [Related]
25. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds. Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482 [TBL] [Abstract][Full Text] [Related]
26. The effects of oxygen affinity and gelation of hemoglobin S crosslinked by reaction with methyl acetimidate. Chao TL; Berenfeld MR; Gelbart T; Gabuzda TG Hemoglobin; 1981; 5(1):47-72. PubMed ID: 7204094 [TBL] [Abstract][Full Text] [Related]
27. Inhibitors of sickling. Mentzer WC Am J Pediatr Hematol Oncol; 1982; 4(3):320-7. PubMed ID: 7149171 [TBL] [Abstract][Full Text] [Related]
28. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Iyamu EW; Turner EA; Asakura T Br J Haematol; 2002 Jul; 118(1):337-43. PubMed ID: 12100171 [TBL] [Abstract][Full Text] [Related]
29. Regioselective covalent modification of hemoglobin in search of antisickling agents. Park S; Hayes BL; Marankan F; Mulhearn DC; Wanna L; Mesecar AD; Santarsiero BD; Johnson ME; Venton DL J Med Chem; 2003 Mar; 46(6):936-53. PubMed ID: 12620071 [TBL] [Abstract][Full Text] [Related]
30. Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin. Omar AM; Mahran MA; Ghatge MS; Bamane FH; Ahmed MH; El-Araby ME; Abdulmalik O; Safo MK Molecules; 2016 Aug; 21(8):. PubMed ID: 27529207 [TBL] [Abstract][Full Text] [Related]
31. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells. Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905 [TBL] [Abstract][Full Text] [Related]
32. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies. Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104 [TBL] [Abstract][Full Text] [Related]
33. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects. Kassa T; Strader MB; Nakagawa A; Zapol WM; Alayash AI Metallomics; 2017 Sep; 9(9):1260-1270. PubMed ID: 28770911 [TBL] [Abstract][Full Text] [Related]
34. Survival rates and properties of sickle cell anemia red cells treated with nitrogen mustard. Roth EF; Wenz B; Lee HB; Fabry M; Chang H; Kaul DK; Baez S; Nagel RL Prog Clin Biol Res; 1987; 240():245-61. PubMed ID: 3615491 [TBL] [Abstract][Full Text] [Related]
35. Synthesis of pyridine derivatives of L-phenylalanine as antisickling reagents. Altman J; Gorecki M; Wilchek M; Votano JR; Rich A J Med Chem; 1984 May; 27(5):596-600. PubMed ID: 6716398 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of erythrocyte sickling by thiol reagents. Garel MC; Domenget C; Galacteros F; Martin-Caburi J; Beuzard Y Mol Pharmacol; 1984 Nov; 26(3):559-65. PubMed ID: 6493211 [TBL] [Abstract][Full Text] [Related]
37. Measurements of red cell deformability and hydration reflect HbF and HbA Parrow NL; Tu H; Nichols J; Violet PC; Pittman CA; Fitzhugh C; Fleming RE; Mohandas N; Tisdale JF; Levine M Blood Cells Mol Dis; 2017 Jun; 65():41-50. PubMed ID: 28472705 [TBL] [Abstract][Full Text] [Related]
38. Established and experimental treatments for sickle cell disease. De Franceschi L; Corrocher R Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275 [TBL] [Abstract][Full Text] [Related]